StoxGlenmark Pharmaceuticals vs Alkem Laboratories: share price & financials comparison
NSE: GLENMARK vs ALKEM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glenmark Pharmaceuticals vs Alkem Laboratories at a glance
Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of ₹73,095 Cr, against ₹63,326 Cr for Alkem Laboratories (ALKEM). Over the past year Glenmark Pharmaceuticals has returned +40.5%, compared with -4.3% for Alkem Laboratories. On valuation, Alkem Laboratories trades at a lower P/E of 29.4 versus 82.5. Alkem Laboratories earns a higher return on equity (15.6% vs 7.9%). Glenmark Pharmaceuticals comes out ahead on financial health, momentum and technicals. Alkem Laboratories comes out ahead on size, valuation, profitability and growth. Across the scored metrics below, Glenmark Pharmaceuticals leads on 8 and Alkem Laboratories on 10. On StoxGud's 10-point checklist, Glenmark Pharmaceuticals scores 5/10 and Alkem Laboratories scores 6/10.
| Metric | Glenmark Pharmaceuticals | Alkem Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹73,095 Cr | ₹63,326 Cr |
| Revenue (latest FY) | ₹16,983 Cr | ₹14,712 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹2,302 Cr |
| Valuation | ||
| P/E | 82.5 | 29.4 |
| P/B | 6.52 | 4.58 |
| Dividend yield | 0.19% | 0.97% |
| Profitability | ||
| Return on equity | 7.9% | 15.6% |
| Net profit margin | 5.6% | 14.3% |
| Operating margin | 20.3% | 20.1% |
| Growth | ||
| Revenue growth (YoY) | -31.3% | +10.9% |
| Net profit growth (YoY) | -100.0% | -21.7% |
| Revenue CAGR (multi-year) | +9.2% | +9.9% |
| Financial health | ||
| Debt to equity | 0.08 | 0.12 |
| Momentum | ||
| 1-month return | +13.5% | -1.0% |
| 1-year return | +40.5% | -4.3% |
| 3-year CAGR | +50.8% | +11.5% |
| 5-year CAGR | +37.6% | +8.0% |
| 10-year CAGR | +11.2% | +13.0% |
| Distance from 52W high | +0.0% | -10.1% |
| Technicals | ||
| RSI (14) | 79 | 71 |
| Price vs 200-day avg | +15.9% | -2.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glenmark Pharmaceuticals | Alkem Laboratories |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 5/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glenmark Pharmaceuticals or Alkem Laboratories?
Glenmark Pharmaceuticals has a market cap of ₹73,095 Cr and Alkem Laboratories has a market cap of ₹63,326 Cr as of 06 Nov 2026.
Which has a lower P/E, Glenmark Pharmaceuticals or Alkem Laboratories?
Alkem Laboratories has the lower P/E: Glenmark Pharmaceuticals trades at 82.5 and Alkem Laboratories at 29.4.
Which gave better returns in the last year, Glenmark Pharmaceuticals or Alkem Laboratories?
Glenmark Pharmaceuticals did better: Glenmark Pharmaceuticals returned +40.5% and Alkem Laboratories returned -4.3% over one year.
Is Glenmark Pharmaceuticals or Alkem Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Glenmark Pharmaceuticals scores 5/10 and Alkem Laboratories scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.